» Articles » PMID: 33636206

Integrated Clinicopathological and Immunohistochemical Analysis of Gastric Adenocarcinoma with Hepatoid Differentiation: an Exploration of Histogenesis, Molecular Characteristics, and Prognostic Markers

Overview
Journal Hum Pathol
Specialty Pathology
Date 2021 Feb 26
PMID 33636206
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

In addition to hepatoid adenocarcinoma (HAC), gastric adenocarcinoma with enteroblastic differentiation (GAED) and common adenocarcinoma (COM) could also show hepatoid differentiation, which presents a poor prognosis. To elucidate the histogenesis and development of gastric cancer with hepatoid differentiation, we identified 55 cases by histological morphology and a panel of markers, including α-fetoprotein (AFP), Glypican 3 (GPC3) and SALL4, then clinicopathological parameters, pathomorphological characteristics, mucin phenotypes, molecular features, Immunoscore and survival analysis were assessed. A mixture of three types (COM + GAED + HAC) was most commonly observed in the same case, and typical transitions between each histological subtype were frequently seen. Hyaline globule and pink amorphous substance were often present. HER2 was amplified in 21.8% of cases. All the tumors showed intestinal phenotype (69.1%) and mixed gastric/intestinal phenotype (30.9%) and were all defined to chromosomal instable (CIN)/genomically stable (GS) group. Considering that 83.6% cases presented TP53 gene mutation phenotype and 61.8% cases showed ≥10% aberrant E-cadherin expression, the precise molecule classification is ambiguous. Survival analysis showed that patients with high SALL4 expression, high preoperative serum AFP level, or low Immunoscore had a significantly poor overall survival (OS). Moreover, SALL4, HER2, and Immunoscore had an independent influence on OS. In conclusion, we suggest that the development of gastric adenocarcinoma with hepatoid differentiation might a continuously progressive profile: from intestinal-type COM adenocarcinoma to GAED and then HAC. CIN/GS subtypes might be where they belonged. SALL4, HER2, and Immunoscore may be potential therapeutic targets.

Citing Articles

Case report: Chemotherapy plus sintilimab for the treatment of gastroesophageal junction hepatoid adenocarcinoma with liver metastasis: a case study with literature review.

Lu G, Tu J, Tu J, Jiang R Front Immunol. 2025; 16:1513604.

PMID: 39931054 PMC: 11808132. DOI: 10.3389/fimmu.2025.1513604.


Genomic landscape and potential therapeutic targets in alpha-fetoprotein-producing gastric cancer.

Zan L, Zhang X, Shen L, Zhao Q, Tan D, Peng X Gastric Cancer. 2025; .

PMID: 39928247 DOI: 10.1007/s10120-025-01594-x.


Case report: Significant response of alpha-fetoprotein-producing gastric cancer from combined chemotherapy and immunotherapy.

Da X, Juan Z, Zhijun H, Zhongchuan L Front Immunol. 2024; 15:1448875.

PMID: 39530092 PMC: 11551777. DOI: 10.3389/fimmu.2024.1448875.


Recent Advances in Pathology of Intrahepatic Cholangiocarcinoma.

Choi J, Thung S Cancers (Basel). 2024; 16(8).

PMID: 38672619 PMC: 11048541. DOI: 10.3390/cancers16081537.


Immunohistochemical characteristics and potential therapeutic regimens of hepatoid adenocarcinoma of the stomach: a study of 139 cases.

Yang X, Wu Y, Wang A, Ma X, Zhou K, Ji K J Pathol Clin Res. 2023; 10(1):e343.

PMID: 37974386 PMC: 10766033. DOI: 10.1002/cjp2.343.